{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:48:17Z","timestamp":1792054097298,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008212","name":"College of Medicine, Drexel University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.addbeh.2026.108878","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:28:48Z","timestamp":1791613728000},"page":"108878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanisms"],"prefix":"10.1016","volume":"185","author":[{"given":"Arundhati","family":"Nittur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Belzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-8643","authenticated-orcid":false,"given":"Chandra","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addbeh.2026.108878_b0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/medsci13030136","article-title":"Mechanisms of GLP-1 in modulating craving and addiction: Neurobiological and translational insights","volume":"13","author":"Alves","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.addbeh.2026.108878_b0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/B978-0-12-801284-0.00010-5","article-title":"Neuroimmune basis of alcoholic brain damage","volume":"118","author":"Crews","year":"2014","journal-title":"International Review of Neurobiology"},{"key":"10.1016\/j.addbeh.2026.108878_b0015","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.4103\/1673-5374.389626","article-title":"Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain","volume":"19","author":"Diz-Chaves","year":"2024","journal-title":"Neural Regeneration Research"},{"key":"10.1016\/j.addbeh.2026.108878_b0020","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.addbeh.2026.108878_b0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.addbeh.2026.108878_b0030","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/acer.70110","article-title":"Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial","volume":"49","author":"Hviid","year":"2025","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/j.addbeh.2026.108878_b0035","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/acer.70041","article-title":"Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption","volume":"49","author":"Jensen","year":"2025","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/j.addbeh.2026.108878_b0040","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.addbeh.2026.108878_b0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.addbeh.2026.108878_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086454","article-title":"Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)","volume":"15","author":"Klausen","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.addbeh.2026.108878_b0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.addbeh.2026.108878_b0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.addbeh.2026.108878_b0065","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","article-title":"Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty","volume":"99","author":"Mark","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2026.108878_b0070","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.addbeh.2026.108878_b0075","article-title":"GLP-1 receptor agonists and alcohol use disorder: a systematic review","volume":"61","author":"Patel","year":"2025","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/j.addbeh.2026.108878_b0080","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.addbeh.2026.108878_b0085","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Scientific Reports"},{"key":"10.1016\/j.addbeh.2026.108878_b0090","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: A case series","volume":"85","author":"Richards","year":"2023","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1016\/j.addbeh.2026.108878_b9000","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.addbeh.2026.108878_b0095","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1017\/neu.2025.6","article-title":"A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder","volume":"37","author":"Zheng","year":"2025","journal-title":"Acta Neuropsychiatr"}],"container-title":["Addictive Behaviors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460326002881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460326002881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:20:39Z","timestamp":1792052439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306460326002881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":20,"alternative-id":["S0306460326002881"],"URL":"https:\/\/doi.org\/10.1016\/j.addbeh.2026.108878","relation":{},"ISSN":["0306-4603"],"issn-type":[{"value":"0306-4603","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanisms","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addbeh.2026.108878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108878"}}